Company Profile
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company provides the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Its portfolio also includes Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors.
It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL). Its portfolio also includes IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma, IMM27M that in Phase Ib/II clinical trial to treat solid tumors, and IMM2520, which is in Phase I clinical trial for solid tumors.
Additionally, it develops IMC-002 for treating autoimmune indications. Its portfolio also includes IMC-001 for the treatment of atherosclerosis, IMM72, IMM7211b, IMM51, IMM38, IMM50, and IMM62 for solid tumors, and IMM40H for liquid/solid tumors.
It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. Incorporated in 2015, ImmuneOnco Biopharmaceuticals (Shanghai) is headquartered in Shanghai, China.